J. Murai

发表

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Y. Pommier, J. Doroshow, Shar-yin N. Huang, 2012, Cancer research.

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Y. Pommier, Joel Morris, J. Doroshow, 2013, Molecular Cancer Therapeutics.

Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum‐based chemotherapy

Y. Pommier, Tetsutaro Hayashi, W. Yasui, 2021, Cancer science.

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Y. Pommier, S. Difilippantonio, W. Figg, 2018, Molecular Cancer Therapeutics.

Therapeutics , Targets , and Chemical Biology Trapping of PARP 1 and PARP 2 by Clinical PARP Inhibitors

Y. Pommier, J. Doroshow, Shar-yin N. Huang, 2012 .

I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel Differential and Common DNA Repair Pathways for Topoisomerase

Y. Pommier, Terukazu Nakamura, T. Miki, 2017 .

Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).

Y. Pommier, Shar-yin N. Huang, C. Marchand, 2014, DNA repair.

Regulation of the Fanconi anemia pathway by a SUMO-like delivery network.

A. D’Andrea, Kailin Yang, George-Lucian Moldovan, 2011, Genes & development.

Response to Letter to the Editor by Yang et al.

Y. Pommier, J. Murai, R. Hassan, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Insulation of the Ubiquitous Rxrb Promoter from the Cartilage-specific Adjacent Gene, Col11a2*

H. Yoshikawa, J. Murai, N. Tsumaki, 2008, Journal of Biological Chemistry.

Title The POLD 3 subunit of DNA polymerase δ can promotetranslesion synthesis independently of DNA polymerase

Y. Pommier, J. Sale, A. Lehmann, 2019 .

In vivo evidence for translesion synthesis by the replicative DNA polymerase δ

Mohiuddin, Z. Livneh, J. Sale, 2016, Nucleic acids research.

The POLD3 subunit of DNA polymerase δ can promote translesion synthesis independently of DNA polymerase ζ

Y. Pommier, J. Sale, A. Lehmann, 2015, Nucleic acids research.

BAMscale: quantification of next-generation sequencing peaks and generation of scaled coverage tracks

Roberto Vera Alvarez, D. Landsman, Y. Pommier, 2020, Epigenetics & Chromatin.

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

Y. Pommier, H. Sugimura, H. Miyajima, 2020, BMC Cancer.

SUMO‐targeted ubiquitin ligase RNF4 plays a critical role in preventing chromosome loss

J. Kobayashi, K. Hirota, H. Sasanuma, 2014, Genes to cells : devoted to molecular & cellular mechanisms.

Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes

J. Murai, H. Onji, 2022, Cancer science.

PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers

Y. Pommier, J. Murai, 2019, Annual Review of Cancer Biology.

The evolving landscape of predictive biomarkers of response to PARP inhibitors.

Y. Pommier, J. Murai, Anish Thomas, 2018, The Journal of clinical investigation.

TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs

Y. Pommier, W. Gmeiner, Shar-yin N. Huang, 2013, Nucleic acids research.

Classification of PARP Inhibitors Based on PARP Trapping and Catalytic Inhibition, and Rationale for Combinations with Topoisomerase I Inhibitors and Alkylating Agents

Y. Pommier, J. Murai, 2015 .

Metabolic clogging of mannose triggers genomic instability via dNTP loss in human cancer cells

H. Freeze, Takehiro Suzuki, N. Dohmae, 2022, bioRxiv.

TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1

Y. Pommier, D. Huylebroeck, Z. Zeng, 2012, Nucleic acids research.

Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1.

Y. Pommier, J. Murai, 2019, Cancer research.

Abstract CN05-01: PARP inhibitors: Trapping of PARP and rational for combinations.

Y. Pommier, Joel Morris, J. Doroshow, 2013 .

TDP 2 promotes repair of topoisomerase I mediated DNA damage in the absence of TDP 1

Y. Pommier, D. Huylebroeck, Z. Zeng, 2019 .

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer

Y. Pommier, A. Ballestrero, D. Bedognetti, 2017, Journal of Translational Medicine.

Bone Morphogenetic Proteins in Bone Stimulate Osteoclasts and Osteoblasts During Bone Development

H. Yoshikawa, J. Murai, N. Tsumaki, 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice

Y. Mishina, Yuuki Imai, S. Kato, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Discovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2H)-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 Inhibitors

Frank R. Fronczek, Yves Pommier, Junko Murai, 2014, Journal of medicinal chemistry.

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.

Y. Pommier, M. Miettinen, J. Murai, 2019, Pharmacology & therapeutics.

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

Yves Pommier, Junko Murai, Justin R Pritchard, 2017, Nature Medicine.

Asymmetric inhibition of spicule formation in sea urchin embryos with low concentrations of gadolinium ion

J. Murai, H. Kuroda, R. Kuroda, 2010, Development, growth & differentiation.

Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway

Y. Pommier, J. Murai, U. Jo, 2021, iScience.

SLFN11 Blocks Stressed Replication Forks Independently of ATR.

Y. Pommier, M. Aladjem, V. Rajapakse, 2018, Molecular cell.

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors

Y. Pommier, S. Bates, V. Rajapakse, 2018, Clinical Cancer Research.

A subset of platinum-containing chemotherapeutic agents kill cells by inducing ribosome biogenesis stress rather than by engaging a DNA damage response

Y. Pommier, M. Hemann, J. Pritchard, 2017 .

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

Y. Pommier, M. Hemann, J. Pritchard, 2017, Nature Medicine.

Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel

Yves Pommier, Shunichi Takeda, Junko Murai, 2013, Molecular Cancer Therapeutics.

Targeting DNA repair and replication stress in the treatment of ovarian cancer

J. Murai, 2017, International Journal of Clinical Oncology.

SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243

Y. Pommier, L. Jenkins, Shar-yin N. Huang, 2021, Cancer Research.

Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development

Y. Pommier, N. Onishi, F. Elloumi, 2021, PloS one.

Epigenetic suppression of SLFN11 in germinal center B cells in the process of the dynamic expression change during B-cell development

H. Arima, H. Sasanuma, S. Takeda, 2020, bioRxiv.

The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib

Y. Pommier, K. Kelly, J. Murai, 2019, Clinical Cancer Research.

The germline factor DDX4 contributes to the chemoresistance of small cell lung cancer cells

D. Barbie, N. Ahsan, N. Tapinos, 2022, bioRxiv.

Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy

Y. Ohba, N. Sakamoto, J. Murai, 2023, Frontiers in Oncology.

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors

Y. Pommier, J. Murai, U. Jo, 2021, Proceedings of the National Academy of Sciences.

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.

M. Tomita, Y. Pommier, Sai-Wen Tang, 2020, Cell reports.

Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-Schlafen 11and low-MGMT expression.

Y. Pommier, M. Raffeld, R. Chari, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

Y. Pommier, Guoying Yu, Sai-Wen Tang, 2016, Oncotarget.

Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers

Pham Quoc Thang, K. Tanabe, H. Ohdan, 2021, British Journal of Cancer.

Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition

James H. Doroshow, Yves Pommier, Shunichi Takeda, 2014, The Journal of Pharmacology and Experimental Therapeutics.

PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage

Y. Pommier, V. Schreiber, D. Biard, 2014, Nucleic acids research.

ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair

Y. Pommier, A. Yasui, M. Hiraoka, 2017, PloS one.

Cancer Biology and Signal Transduction Stereospeci fi c PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Y. Pommier, Joel Morris, J. Doroshow, 2014 .

The USP1/UAF1 Complex Promotes Double-Strand Break Repair through Homologous Recombination

A. D’Andrea, K. Hirota, Kailin Yang, 2011, Molecular and Cellular Biology.

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma

P. Meltzer, J. Khan, Y. Pommier, 2015, Clinical Cancer Research.

Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.

Y. Pommier, Ruili Huang, A. Jadhav, 2014, DNA repair.

Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Repairs DNA Damage Induced by Topoisomerases I and II and Base Alkylation in Vertebrate Cells*

Y. Pommier, Shar-yin N. Huang, S. Takeda, 2012, The Journal of Biological Chemistry.

Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes dwarfism with osteopenia

K. Miyazono, H. Yoshikawa, T. Ochi, 2004, The Journal of cell biology.

Smad7 Inhibits Chondrocyte Differentiation at Multiple Steps during Endochondral Bone Formation and Down-regulates p38 MAPK Pathways*♦

H. Yoshikawa, J. Murai, N. Tsumaki, 2008, Journal of Biological Chemistry.

Successful Treatment of Acute Uric Acid Nephropathy with Rasburicase in a Primary Central Nervous System Lymphoma Patient Showing a Dramatic Response to Methotrexate—Case Report

Y. Fujii, A. Kakita, J. Murai, 2022, Journal of clinical medicine.

Title ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair

Y. Pommier, A. Yasui, M. Hiraoka, 2020 .

Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition

Y. Pommier, Joel Morris, J. Doroshow, 2014 .

Mitochondrial tyrosyl‐DNA phosphodiesterase 2 and its TDP2S short isoform

Y. Pommier, S. Varma, S. Kelley, 2018, EMBO reports.

SLFN 11 is a transcriptional target of EWS-FLI 1 and a determinant of drug response in Ewing ’ s sarcoma

J. Khan, Y. Pommier, S. Bilke, 2015 .

Biochemical Assays for the Discovery of TDP1 Inhibitors

Y. Pommier, W. L. Jorgensen, A. Jadhav, 2014, Molecular Cancer Therapeutics.

Models and Technologies Biochemical Assays for the Discovery of TDP 1 Inhibitors

Y. Pommier, W. L. Jorgensen, A. Jadhav, 2014 .

De novo deoxyribonucleotide biosynthesis regulates cell growth and tumor progression in small-cell lung carcinoma

T. Soga, H. Makinoshima, J. Murai, 2021, Scientific Reports.

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

Y. Pommier, P. Steeg, J. Nair, 2020, Oncogene.

Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.

Jung-Min Lee, J. Murai, Brittany M. Haynes, 2018, Cancer treatment reviews.

BAMscale: quantification of DNA sequencing peaks and generation of scaled coverage tracks

Hongliang Zhang, Leonardo Mariño-Ramírez, David Landsman, 2019, bioRxiv.

Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq

Y. Pommier, V. Rajapakse, W. Yasui, 2020, Virchows Archiv.

Low-intensity pulsed ultrasound increases bone ingrowth into porous hydroxyapatite ceramic

Y. Harada, H. Yoshikawa, S. Iwabuchi, 2007, Journal of Bone and Mineral Metabolism.

Synergistic effects of PARP inhibitors by Schlafen 11 and BRCA2-deficiency through accumulation of single-strand DNA gaps behind a fork

N. Onishi, S. Higashiyama, J. Murai, 2023, bioRxiv.

O6.1Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations

Y. Pommier, J. Murai, 2015 .

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer

Y. Pommier, A. Ballestrero, D. Bedognetti, 2017, Journal of Translational Medicine.

SLFN11 Blocks Stressed Replication Forks Independently of ATR.

Y. Pommier, M. Aladjem, V. Rajapakse, 2018, Molecular cell.

BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.

Y. Pommier, J. Murai, 2023, Cancer research.

Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice

Y. Mishina, Yuuki Imai, S. Kato, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The USP1/UAF1 Complex Promotes Double-Strand Break Repair through Homologous Recombination

A. D’Andrea, K. Hirota, Kailin Yang, 2011, Molecular and Cellular Biology.

Smad 7 Inhibits Chondrocyte Differentiation at Multiple Steps during Endochondral Bone Formation and Down-regulates p 38 MAPK Pathways *

H. Yoshikawa, J. Murai, N. Tsumaki, 2008 .